Equillium Inc.
| NASDAQ: EQ | Healthcare / Biotechnology / USA |
| 6.41 | -0.1700 | -2.58% | Vol 90.53K | 1Y Perf 150.84% |
| Apr 13th, 2021 14:30 DELAYED |
| BID | 6.40 | ASK | 6.46 | ||
| Open | 6.68 | Previous Close | 6.58 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 16.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 149.61 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
| Market Cap | 186.15M | Earnings Rating | Sell | |
| Price Range Ratio 52W % | 16.37 | Earnings Date | 12th May 2021 |
Today's Price Range 6.336.68 | 52W Range 2.3727.05 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.08% | ||
| 1 Month | -16.81% | ||
| 3 Months | 18.35% | ||
| 6 Months | 6.99% | ||
| 1 Year | 150.84% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -51.66 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -40.87 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -38.10 | |||
Return on invested Capital Q | -10.36 | |||
Return on invested Capital Y | -43.90 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -4.80 | ||||
| 2.94 | ||||
| - | ||||
| - | ||||
| -11.10 | ||||
| -1.21 | ||||
| 2.94 | ||||
| 2.41 | ||||
| 133.38M | ||||
| Forward PE | -4.21 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 11.30 | ||||
| 11.80 | ||||
| 0.11 | ||||
| 0.14 | ||||
| -26.10 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.38 | -0.36 | 5.26 |
| Q03 2020 | -0.41 | -0.31 | 24.39 |
| Q02 2020 | -0.44 | -0.37 | 15.91 |
| Q01 2020 | -0.42 | -0.45 | -7.14 |
| Q04 2019 | -0.40 | -0.44 | -10.00 |
| Q03 2019 | -0.36 | -0.35 | 2.78 |
| Q02 2019 | -0.34 | -0.35 | -2.94 |
| Q01 2019 | -0.27 | -0.34 | -25.93 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.33 | -6.45 | Negative |
| 6/2021 QR | -0.34 | -9.68 | Negative |
| 12/2021 FY | -1.40 | 0.71 | Positive |
| 12/2022 FY | -1.66 | 9.78 | Positive |
| Next Report Date | 12th May 2021 |
| Estimated EPS Next Report | -0.33 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 90.53K |
| Shares Outstanding | 29.04M |
| Trades Count | 1.03K |
| Dollar Volume | 2.11M |
| Avg. Volume | 449.88K |
| Avg. Weekly Volume | 116.07K |
| Avg. Monthly Volume | 194.79K |
| Avg. Quarterly Volume | 443.46K |
Equillium Inc. (NASDAQ: EQ) stock closed at 6.58 per share at the end of the most recent trading day (a -5.87% change compared to the prior day closing price) with a volume of 158.32K shares and market capitalization of 186.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 26 people. Equillium Inc. CEO is Bruce D. Steel.
The one-year performance of Equillium Inc. stock is 150.84%, while year-to-date (YTD) performance is 22.99%. EQ stock has a five-year performance of %. Its 52-week range is between 2.37 and 27.05, which gives EQ stock a 52-week price range ratio of 16.37%
Equillium Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 2.94, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.87%, a ROC of -38.10% and a ROE of -51.66%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Equillium Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. Equillium Inc.’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Equillium Inc. is Strong Buy (1), with a target price of $16, which is +149.61% compared to the current price. The earnings rating for Equillium Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Equillium Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Equillium Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.40, ATR14 : 0.85, CCI20 : -87.23, Chaikin Money Flow : -0.19, MACD : -0.14, Money Flow Index : 34.37, ROC : -4.50, RSI : 48.82, STOCH (14,3) : 19.21, STOCH RSI : 0.61, UO : 36.60, Williams %R : -80.79), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Equillium Inc. in the last 12-months were: Jason A. Keyes (Sold 8 000 shares of value $37 914 ), Stephen Connelly (Sold 275 000 shares of value $2 173 870 )
Equillium Inc.
Equillium Inc is a biopharmaceutical company. It is developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Its primary product candidate is itolizumab, which targets the CD6-ALCAM signaling pathway, which helps in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab is the treatment for multiple severe immuno-inflammatory disorders, including graft versus host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.
CEO: Bruce D. Steel
Telephone: +1 858 412-5302
Address: 2223 Avenida De La Playa, La Jolla 92037, CA, US
Number of employees: 26
